Seer Inc Cl A (SEER)

$2.03 +0.05 (2.53%)
Market Cap 110.46M
Revenue (ttm) 14.17M
Net Income (ttm) -86.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -611.15%
Debt to Equity Ratio 0.00
Volume 200,148
Avg Vol 239,200
Day's Range N/A - N/A
Shares Out 55.79M
Stochastic %K 56%
Beta 1.63
Analysts Strong Sell
Price Target $3.00

Company Profile

Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic in...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 453 0000
Website: seer.bio
Address:
3800 Bridge Parkway, Suite 102, Redwood City, United States
annee33
annee33 Feb. 20 at 4:00 PM
$SEER volume alert
0 · Reply
annee33
annee33 Feb. 19 at 6:29 PM
$SEER and $EQ both under the radar biotechs hitting my breakout scan
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 5:35 PM
$SEER Current Stock Price: $2.05 Contracts to trade: $2.5 SEER Feb 20 2026 Call Entry: $0.04 Exit: $0.06 ROI: 71% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
TheTradeXchange
TheTradeXchange Feb. 19 at 12:01 PM
$SEER - Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights
0 · Reply
Dani_G_German
Dani_G_German Feb. 19 at 12:16 AM
$ACRV $SEER
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 6:47 PM
$SEER RSI: 58.93, MACD: 0.0153 Vol: 0.08, MA20: 1.87, MA50: 1.86 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
VolatilityBeta
VolatilityBeta Feb. 17 at 2:49 PM
$SEER Seer is a life sciences tools company developing proteomics technology, facing commercialization challenges in a competitive research tools market.
0 · Reply
Dani_G_German
Dani_G_German Feb. 13 at 6:04 PM
$SEER $ACRV cooking
0 · Reply
TrendBreeze
TrendBreeze Feb. 10 at 1:10 PM
$SEER is a proteomics technology company (Seer, Inc.); commercial adoption by researchers is key to growth.
0 · Reply
Dani_G_German
Dani_G_German Jan. 15 at 2:48 AM
$ACRV $SEER see both of youz above 2
0 · Reply
Latest News on SEER
The Radoff-JEC Group Issues Open Letter to Seer Inc.'s Board of Directors Regarding the Immediate Need for Significant Change

Feb 23, 2026, 8:30 AM EST - 6 hours ago

The Radoff-JEC Group Issues Open Letter to Seer Inc.'s Board of Directors Regarding the Immediate Need for Significant Change

Leading Scientists Demonstrate How Seer's Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026

Feb 19, 2026, 7:00 AM EST - 4 days ago

Leading Scientists Demonstrate How Seer's Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026

Seer to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 18, 2026, 4:05 PM EST - 4 days ago

Seer to Participate in the TD Cowen 46th Annual Health Care Conference

Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Feb 5, 2026, 4:05 PM EST - 17 days ago

Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Nature Genetics Study Validates Seer's Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers

Dec 1, 2025, 7:00 AM EST - 3 months ago

Nature Genetics Study Validates Seer's Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers

Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025

Nov 7, 2025, 7:00 AM EST - 3 months ago

Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025

Seer, Inc. (SEER) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 8:16 PM EST - 3 months ago

Seer, Inc. (SEER) Q3 2025 Earnings Call Transcript

Seer Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 3 months ago

Seer Reports Third Quarter 2025 Financial Results

Seer to Participate in Upcoming November Investor Conferences

Oct 29, 2025, 4:05 PM EDT - 4 months ago

Seer to Participate in Upcoming November Investor Conferences

Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 16, 2025, 4:05 PM EDT - 4 months ago

Seer to Report Third Quarter 2025 Financial Results on November 6, 2025

Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025

Oct 10, 2025, 7:00 AM EDT - 4 months ago

Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025

Seer, Inc. (SEER) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 4:42 PM EDT - 5 months ago

Seer, Inc. (SEER) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Seer Appoints Isaac Ro to its Board of Directors

Sep 2, 2025, 7:00 AM EDT - 6 months ago

Seer Appoints Isaac Ro to its Board of Directors

WGS

Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 26, 2025, 4:05 PM EDT - 6 months ago

Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Seer, Inc. (SEER) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 3:16 AM EDT - 7 months ago

Seer, Inc. (SEER) Q2 2025 Earnings Call Transcript

Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

Aug 6, 2025, 4:05 PM EDT - 7 months ago

Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 31, 2025, 4:05 PM EDT - 7 months ago

Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference

Seer to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 22, 2025, 4:05 PM EDT - 7 months ago

Seer to Report Second Quarter 2025 Financial Results on August 6, 2025

Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

Jun 1, 2025, 7:00 AM EDT - 9 months ago

Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency

May 29, 2025, 7:00 AM EDT - 9 months ago

Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency

Seer, Inc. (SEER) Q1 2025 Earnings Call Transcript

May 13, 2025, 6:47 PM EDT - 10 months ago

Seer, Inc. (SEER) Q1 2025 Earnings Call Transcript

Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

May 13, 2025, 4:05 PM EDT - 10 months ago

Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook

Seer to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 24, 2025, 4:05 PM EDT - 10 months ago

Seer to Report First Quarter 2025 Financial Results on May 13, 2025

Seer, Inc. (SEER) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:09 PM EST - 1 year ago

Seer, Inc. (SEER) Q4 2024 Earnings Call Transcript

Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook

Feb 27, 2025, 4:05 PM EST - 1 year ago

Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook

Seer to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 21, 2025, 7:00 AM EST - 1 year ago

Seer to Participate in the TD Cowen 45th Annual Health Care Conference

Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025

Feb 20, 2025, 7:00 AM EST - 1 year ago

Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025

Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Feb 13, 2025, 4:15 PM EST - 1 year ago

Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference

Jan 2, 2025, 4:05 PM EST - 1 year ago

Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference

Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Nov 21, 2024, 4:05 PM EST - 1 year ago

Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 9:00 PM EST - 1 year ago

Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript

Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific

Nov 6, 2024, 4:03 PM EST - 1 year ago

Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific

Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer's, Lung Cancer, and More at ASHG 2024

Oct 31, 2024, 7:00 AM EDT - 1 year ago

Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer's, Lung Cancer, and More at ASHG 2024

Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer's, Population Health, and Xenotransplantation at HUPO 2024

Oct 21, 2024, 7:00 AM EDT - 1 year ago

Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer's, Population Health, and Xenotransplantation at HUPO 2024

Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 22, 2024, 4:05 PM EDT - 1 year ago

Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Seer Appoints Nicolas Roelofs to its Board of Directors

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Seer Appoints Nicolas Roelofs to its Board of Directors

Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 9, 2024, 7:00 AM EDT - 1 year ago

Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference

Seer to Report Second Quarter 2024 Financial Results on August 8, 2024

Jul 18, 2024, 4:03 PM EDT - 1 year ago

Seer to Report Second Quarter 2024 Financial Results on August 8, 2024

Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery

Jun 11, 2024, 11:11 AM EDT - 1 year ago

Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery

Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ's Early Cancer Detection Study

Jun 2, 2024, 10:55 AM EDT - 1 year ago

Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ's Early Cancer Detection Study

Lab Instrument Industry Update - New Commercial Entrants

May 23, 2024, 9:17 AM EDT - 1 year ago

Lab Instrument Industry Update - New Commercial Entrants

AKYA BNGO CTKB DHR LAB MASS OMIC

Seer Reports First Quarter 2024 Financial Results

May 8, 2024, 4:05 PM EDT - 1 year ago

Seer Reports First Quarter 2024 Financial Results

Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions

May 8, 2024, 4:03 PM EDT - 1 year ago

Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions

Seer to Report First Quarter 2024 Financial Results on May 8, 2024

Apr 23, 2024, 4:05 PM EDT - 1 year ago

Seer to Report First Quarter 2024 Financial Results on May 8, 2024

Seer, Inc. (SEER) Q4 2023 Earnings Call Transcript

Mar 1, 2024, 7:12 AM EST - 2 years ago

Seer, Inc. (SEER) Q4 2023 Earnings Call Transcript

Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook

Feb 29, 2024, 4:05 PM EST - 2 years ago

Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook

Seer to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 21, 2024, 4:05 PM EST - 2 years ago

Seer to Participate in the TD Cowen 44th Annual Health Care Conference

Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery

Feb 6, 2024, 8:00 AM EST - 2 years ago

Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery

Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Feb 1, 2024, 4:05 PM EST - 2 years ago

Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference

Dec 21, 2023, 4:05 PM EST - 2 years ago

Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference

annee33
annee33 Feb. 20 at 4:00 PM
$SEER volume alert
0 · Reply
annee33
annee33 Feb. 19 at 6:29 PM
$SEER and $EQ both under the radar biotechs hitting my breakout scan
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 5:35 PM
$SEER Current Stock Price: $2.05 Contracts to trade: $2.5 SEER Feb 20 2026 Call Entry: $0.04 Exit: $0.06 ROI: 71% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
TheTradeXchange
TheTradeXchange Feb. 19 at 12:01 PM
$SEER - Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights
0 · Reply
Dani_G_German
Dani_G_German Feb. 19 at 12:16 AM
$ACRV $SEER
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 6:47 PM
$SEER RSI: 58.93, MACD: 0.0153 Vol: 0.08, MA20: 1.87, MA50: 1.86 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
VolatilityBeta
VolatilityBeta Feb. 17 at 2:49 PM
$SEER Seer is a life sciences tools company developing proteomics technology, facing commercialization challenges in a competitive research tools market.
0 · Reply
Dani_G_German
Dani_G_German Feb. 13 at 6:04 PM
$SEER $ACRV cooking
0 · Reply
TrendBreeze
TrendBreeze Feb. 10 at 1:10 PM
$SEER is a proteomics technology company (Seer, Inc.); commercial adoption by researchers is key to growth.
0 · Reply
Dani_G_German
Dani_G_German Jan. 15 at 2:48 AM
$ACRV $SEER see both of youz above 2
0 · Reply
Dani_G_German
Dani_G_German Jan. 12 at 2:52 PM
$ACRV $SEER told you!
0 · Reply
Dani_G_German
Dani_G_German Jan. 9 at 6:42 PM
$ACRV $SEER
0 · Reply
ShortyBear_5582
ShortyBear_5582 Jan. 7 at 4:08 PM
$SEER $ACRV $PYXS drop a follow for good info 👇
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 6 at 10:06 PM
$SEER RSI: 52.38, MACD: -0.0328 Vol: 0.02, MA20: 1.82, MA50: 1.97 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Dani_G_German
Dani_G_German Jan. 6 at 8:31 PM
$ACRV anyone in ACRV should also be in $SEER Thank me later
0 · Reply
Dani_G_German
Dani_G_German Dec. 30 at 6:49 PM
$SEER insiders quietly adding
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 24 at 2:43 AM
$SEER Share Price: $1.81 Contract Selected: Apr 17, 2026 $2.5 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.07 – $0.09 Potential Upside: 62% ROI Time to Expiration: 114 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Dani_G_German
Dani_G_German Dec. 23 at 4:46 PM
$SEER am I the only one here?
0 · Reply
Dani_G_German
Dani_G_German Dec. 11 at 8:44 PM
$SEER
0 · Reply
RocketThief
RocketThief Nov. 26 at 4:25 PM
$SEER this is not an exciting company/dtock, but it’s trading well under 50% of cash, has a clean balance sheet, partnership with $TMO, and is growing its modest revenues. Good to trade down here
0 · Reply
d_risk
d_risk Nov. 7 at 3:37 AM
$SEER - Seer Inc. Class A Common Stock - 10Q - Updated Risk Factors SEER’s latest 10-Q flags new risks from its PrognomiQ investment, heightened SOX 404 compliance challenges, expanded FDA and global regulatory uncertainties, deeper internal control and accounting estimate concerns, and more detail on IP disputes, cybersecurity, and ESG exposures. #Biotechnology #Cybersecurity #IntellectualProperty #InternalControls #RegulatoryCompliance 🟢 Added 🟠 Removed https://d-risk.ai/SEER/10-Q/2025-11-06
0 · Reply
prismmarketview
prismmarketview Oct. 16 at 6:32 PM
The biotech equipment sector is entering a new growth cycle — projected to hit $144B by 2030, fueled by advances in cell & gene therapy, automation, and AI-driven manufacturing. Emergers like Cryoport ( $CYRX), Seer ( $SEER), and BioLife Solutions ( $BLFS) are powering this shift with innovations in cold-chain logistics, proteomics, and bioprocessing systems. https://prismmarketview.com/prism-bioview-dive-recent-report-projects-global-biotech-equipment-market-to-accelerate-toward-144bn-by-2030-heres-who-to-watch/
1 · Reply